Business Description
Amgen Inc
NAICS : 325412
SIC : 2834
ISIN : US0311621009
Share Class Description:
AMGN: Ordinary SharesTotal Employee Number:
31,500Compare
Compare
Traded in other countries / regions
AMGN.USAAMGN.CanadaAMGN.Argentina0R0T.UKAMG.GermanyAMGN34.BrazilAMGN.AustriaAMG N.Mexico1AMGN.ItalyAMGN.Chile04332.Hong Kong Index Membership
Dow 30S&P 500NASDAQ 100Russell 1000Russell 3000MSCI World Index IPO Date
1983-06-17Description
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.24 | |||||
Equity-to-Asset | 0.12 | |||||
Debt-to-Equity | 4.9 | |||||
Debt-to-EBITDA | 3.25 | |||||
Interest Coverage | 4.28 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 2.35 | |||||
Beneish M-Score | -2.62 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11.7 | |||||
3-Year EBITDA Growth Rate | 11.5 | |||||
3-Year EPS without NRI Growth Rate | 7.3 | |||||
3-Year FCF Growth Rate | -2.7 | |||||
3-Year Book Growth Rate | 32.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 5.54 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 4.01 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 69.74 | |||||
9-Day RSI | 68.39 | |||||
14-Day RSI | 68.67 | |||||
3-1 Month Momentum % | 12.02 | |||||
6-1 Month Momentum % | 0.5 | |||||
12-1 Month Momentum % | 33.48 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.37 | |||||
Quick Ratio | 1.13 | |||||
Cash Ratio | 0.55 | |||||
Days Inventory | 198.39 | |||||
Days Sales Outstanding | 88.39 | |||||
Days Payable | 88.1 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 2.25 | |||||
Dividend Payout Ratio | 0.44 | |||||
3-Year Dividend Growth Rate | 7.1 | |||||
Forward Dividend Yield % | 2.29 | |||||
5-Year Yield-on-Cost % | 3.37 | |||||
3-Year Average Share Buyback Ratio | -0.3 | |||||
Shareholder Yield % | 3.32 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 69.52 | |||||
Operating Margin % | 29.99 | |||||
Net Margin % | 22.95 | |||||
EBITDA Margin % | 46.26 | |||||
FCF Margin % | 26.71 | |||||
OCF Margin % | 32.75 | |||||
ROE % | 93.84 | |||||
ROA % | 9.57 | |||||
ROIC % | 14.8 | |||||
3-Year ROIIC % | -3.33 | |||||
ROC (Joel Greenblatt) % | 160.57 | |||||
ROCE % | 19.13 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 8 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 27.6 | |||||
Forward PE Ratio | 18.18 | |||||
PE Ratio without NRI | 19.85 | |||||
Shiller PE Ratio | 33.97 | |||||
Price-to-Owner-Earnings | 21.38 | |||||
PEG Ratio | 2.54 | |||||
PS Ratio | 6.33 | |||||
PB Ratio | 20.54 | |||||
Price-to-Free-Cash-Flow | 23.7 | |||||
Price-to-Operating-Cash-Flow | 19.33 | |||||
EV-to-EBIT | 21.88 | |||||
EV-to-Forward-EBIT | 18.57 | |||||
EV-to-EBITDA | 16.08 | |||||
EV-to-Forward-EBITDA | 15.96 | |||||
EV-to-Revenue | 7.44 | |||||
EV-to-Forward-Revenue | 7 | |||||
EV-to-FCF | 27.85 | |||||
Price-to-GF-Value | 1.21 | |||||
Price-to-Projected-FCF | 1.93 | |||||
Price-to-DCF (Earnings Based) | 1.5 | |||||
Price-to-DCF (FCF Based) | 2.05 | |||||
Price-to-Median-PS-Value | 1.17 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.94 | |||||
Earnings Yield (Greenblatt) % | 4.57 | |||||
FCF Yield % | 4.24 | |||||
Forward Rate of Return (Yacktman) % | 13.84 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AMGN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Ā
Total Annual Return % Ā
Amgen Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 38,095 | ||
| EPS (TTM) ($) | 16.09 | ||
| Beta | -0.0871 | ||
| 3-Year Sharpe Ratio | 0.63 | ||
| 3-Year Sortino Ratio | 1.03 | ||
| Volatility % | 28.01 | ||
| 14-Day RSI | 68.67 | ||
| 14-Day ATR ($) | 9.595603 | ||
| 20-Day SMA ($) | 430.12725 | ||
| 12-1 Month Momentum % | 33.48 | ||
| 52-Week Range ($) | 269.77 - 447.03 | ||
| Shares Outstanding (Mil) | 540.63 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Amgen Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Amgen Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-12 | In 161 days | ||
| Fourth quarter earnings conference call for 2026 | 2027-02-03 13:30 | In 153 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-03 | In 152 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-04 13:30 | In 62 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 61 days | ||
| USD 2.520000 Cash Dividend | 2026-08-21 | 433.73 (-0.47%) | ||
| Second quarter earnings conference call for 2026 | 2026-08-04 13:30 | 378.87 (-2.48%) | ||
| Second quarter earnings results for 2026 | 2026-08-04 | 378.87 (-2.48%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 09:20 | 345.73 (-1.03%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 09:55 | 338.22 (+3.40%) |
Show
Entries
Amgen Inc Frequently Asked Questions
What is Amgen Inc(AMGN)'s stock price today?
The current price of AMGN is $444.12. The 52 week high of AMGN is $447.03 and 52 week low is $269.77.
When is next earnings date of Amgen Inc(AMGN)?
The next earnings date of Amgen Inc(AMGN) is 2026-11-04 Est..
Does Amgen Inc(AMGN) pay dividends? If so, how much?
TheĀ Dividend Yield % Ā of Amgen Inc(AMGN) is 2.25% (As of Today), HighestĀ Dividend Payout RatioĀ of Amgen Inc(AMGN) was 0.46. The lowest was 0.34. And the median was 0.4. The Ā Forward Dividend Yield % of Amgen Inc(AMGN) is 2.29%. For more information regarding to dividend, please check our Dividend Page.
Guru Commentaries on NAS:AMGN
Smead Value Fund
Neutral
2025 Q1
Smead Value Fund
Ā· 26 holdings
What the manager wrote
Amgen is listed as one of the top ten holdings in the Smead Value Fund as of March 31, 2025, comprising 5.44% of the portfolio. However, there is no specific argument or directional language provided regarding its future performance or valuation in the passages.
Press Release
Articles on Amgen Inc
Headlines
See More- 1
Sep 02, 2026
Amgen slapped with U.K. suspension of rare-disorder therapy Tavneos
Seeking Alpha ā¢ 6:12am
Aug 31, 2026
4 stocks to watch on Monday: AMGN, LLY, ARM, and MSTR
Seeking Alpha ā¢ 7:43am
Amgen's Repatha cuts death risk by 20% in heart study
Seeking Alpha ā¢ 4:07am
Aug 21, 2026
Lawmakers ask FDA to scrutinize Chinese trials amid deaths - report
Seeking Alpha ā¢ 11:13am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers